Within synthetic routes targeting ATP-competitive inhibitors, Methyl 2-(2-hydroxy-4,5-dimethoxybenzamido)thiazole-4-carboxylate functions as a hinge-binding mimetic fragment. The 2-aminothiazole core presents a hydrogen-bond donor–acceptor pair that projects the 4,5-dimethoxy-2-hydroxybenzamide motif into the solvent-accessible region of the kinase pocket, a geometry confirmed by co-crystal structures of related analogues in the protein data bank. For regulatory starting material designation under ICH Q7, this intermediate is isolated at a chromatographic purity of 98.7% (HPLC, λ = 254 nm, area normalization) with residual palladium controlled to below 10 ppm when preceded by a Suzuki-type fragment elaboration. The hydroxyl and ester groups impose strict constraints on downstream coupling: the methyl ester is retained until the penultimate step to avoid premature acid-mediated decarboxylation, and the phenolic –OH requires temporary protection with a trimethylsilyl group during Buchwald–Hartwig aminations conducted at 85 °C in degassed 1,4-dioxane. In a representative kilo-scale campaign executed in a 100 L glass-lined reactor, the protected intermediate is coupled to a chloropyrimidine partner using Pd2(dba)3/Xantphos at a catalyst loading of 0.8 mol%, yielding the biaryl after TBAF-mediated desilylation. The final drug substance falls into the category of investigational tyrosine kinase inhibitors under evaluation in accordance with FDA 21 CFR 312.23 (IND content and format), with the intermediate’s batch records audited against ISO 13485:2016 documentation standards when the product is designated for a therapeutic medical device combination.
What Limits the Direct Hydrogenation of the Thiazole Ring Without Cleaving the 2-Benzamido Bridge?
Catalytic hydrogenation of the thiazole core to the corresponding thiazolidine, required for certain central nervous system drug candidates, encounters a selectivity bottleneck due to catalyst poisoning by the sulfur atom and the free phenolic –OH group. When the reaction is attempted in a ThalesNano H-Cube Pro continuous flow system with a 30 mm CatCart packed with 5% Rh/Al2O3, deactivation occurs after a throughput of only 0.8 mol of substrate per gram of catalyst, as measured by a drop in conversion from 94% to below 15% within three residence cycles. To circumvent this, the process is re-engineered by first converting the phenol to its methyl ether using dimethyl sulfate (1.05 eq) in acetone with anhydrous K2CO3 at reflux. The masked substrate is then hydrogenated in a trickle-bed reactor operating at 50 °C and 10 bar H2 pressure, with a liquid hourly space velocity of 0.4 h⁻¹, which restores catalyst lifetime to over 72 hours continuous runtime. The hydrogenation step is PAT-monitored via inline ReactIR to track the disappearance of the imine stretch at 1615 cm⁻¹. Post-hydrogenation, the methyl ether is cleaved by treatment with BBr3 (1.0 M in DCM) at −78 °C under strictly anhydrous conditions—moisture ingress above 200 ppm in the headspace nitrogen triggers rapid ester hydrolysis to the carboxylic acid, which then decarboxylates at ambient temperature. The end product, a C4-substituted thiazolidine-4-carboxylate, is formulated as the hydrochloride salt for improved bioavailability in rodent models, with residual boron removed via methanol evaporation cycles until ICP-OES analysis confirms boron < 50 µg/g, aligning with the residual metals limits of USP 233.
Incorporation of the intact molecule into succinate dehydrogenase inhibitor (SDHI) screening cascades for cereal pathogen control exploits the 4,5-dimethoxy substitution pattern as a lipophilic tuning handle. In contrast to the pharmaceutical routes, the ester moiety is deliberately hydrolyzed early to the free carboxylic acid using LiOH in THF/water (3:1 v/v) at 0 °C, yielding the corresponding acid within 45 minutes and avoiding ring-opening byproducts observed with NaOH. The acid is then converted to its corresponding acyl chloride via oxalyl chloride and catalytic DMF in dichloromethane, which is immediately reacted with substituted anilines to generate a library of secondary amides for in vivo testing against Septoria tritici and Puccinia striiformis. The formulation for glasshouse trials consists of an emulsifiable concentrate containing 100 g/L of the test compound, 150 g/L of an alkylbenzene sulfonate calcium salt (CAS 26264-06-2), and Solvesso 200 ND to volume. Translaminar movement, monitored by LC-MS/MS quantification in leaf apoplast washings, is enhanced when log P is maintained between 2.8 and 3.4, a window in which the dimethoxybenzamide analogue outperforms the 4-methoxy-only congener by a factor of 1.7. Field-scale manufacturing intermediates are processed in conformance with the OECD Guideline 509 (Crop Field Trials), and the analytical release specification demands absence of any single unknown impurity exceeding 0.10% area by UPLC-UV at 230 nm.
When Melt Compounding Exposes Instability: A Polyolefin Copper Deactivator Employing This Benzamide-Thiazole Motif
Oxidative degradation of high-voltage XLPE cable insulation in the presence of copper contaminants is mitigated by the addition of metal deactivators composed of an ortho-hydroxybenzamide pharmacophore. This compound, at an optimized let-down ratio of 0.08 wt% in a linear low-density polyethylene masterbatch, is co-fed with hindered phenolic antioxidant Irganox 1010 (0.15 wt%) and a phosphite process stabilizer into a Coperion ZSK 45 mm twin-screw extruder with an L/D ratio of 44:1. The screw profile incorporates an intensive kneading block zone set to 190 °C, but thermal gravimetric analysis via ASTM E2550-21 at 10 K/min under nitrogen indicates the onset of weight loss at 212 °C, prescribing that the barrel temperature in downstream conveying elements must not exceed 200 °C. Incompatibility with basic fillers is evident: the presence of untreated magnesium hydroxide at loadings above 30 phr accelerates gelling of the compound at the die exit due to complexation-triggered crosslinking; neutralization with stearic acid-coated grades (Mg(OH)₂ type LK-02A) prior to compounding is mandatory. Long-term thermal endurance testing of the finished cable insulation, conducted on 0.5 mm pressed plaques per IEC 60216-1, shows time-to-failure at 135 °C extended from 1,800 hours (blank formulation with copper) to over 12,000 hours when this benzamide-thiazole derivative is present, measured by the retention of elongation at break above 50% absolute. All analysis certifies compliance with the heavy metal thresholds of EU Directive 2011/65/EU (RoHS 2) for electrical equipment placed on the market.
An Intermediate That Provides ¹⁸F-Labeling Handles for PET Tracer Synthesis
Positron emission tomography imaging of neuroinflammation relies on radiotracers with rapid brain uptake and selective binding to the translocator protein (TSPO). This carboxymethyl ester intermediate serves as a precursor for the introduction of a methoxy-substituted quinazoline or imidazopyridine moiety, with the 4,5-dimethoxy groups providing a signature mass shift that facilitates metabolic stability assessment via LC-HRMS. The synthetic sequence in a radiochemistry hot cell is initiated by hydrolysis of the methyl ester to the acid using 1.0 M lithium hydroxide in MeOH/H₂O at 60 °C for 25 minutes, followed by amide coupling to a 2-fluoroethyl-1-amine building block pre-loaded on a C18 solid-phase extraction cartridge. Radiofluorination is conducted using a GE TRACERlab FXFN module: the tosylate precursor is reacted with dried [¹⁸F]KF-Kryptofix 2.2.2 in anhydrous MeCN at 85 °C for 15 minutes. The crude product is purified on a semi-preparative HPLC column (Phenomenex Luna C18(2), 250 × 10 mm, 5 µm) eluting with 55% 0.1% H3PO4/MeCN at 4 mL/min. The final formulated product, a sterile solution in 10% ethanolic saline, must pass a bubble-point filter integrity test per ISO 13408-2:2018 and exhibit radiochemical purity above 99.0% by radio-TLC (silica gel, EtOAc/hexane 7:3) and radio-HPLC. The specific activity at end of synthesis exceeds 120 GBq/µmol. The synthetic protocol aligns with the principles of EudraLex Volume 4, Annex 3 (Manufacture of Radiopharmaceuticals), and precursor qualification requires an endotoxin level < 0.25 EU/mg as per Ph. Eur. 2.6.14.
In analytical reagent manufacture, the ortho-hydroxyl and heterocyclic nitrogen atoms create a tridentate ligand pocket selective for Fe(III) over Fe(II) in acidic sulfate media, a discrimination utilized for spectrophotometric detection of iron in boiler feedwater post-oxygen scavenger treatment. The compound is processed into a 0.02% w/v solution in a mixed solvent of ethanol and 0.1 M acetate buffer at pH 4.5, which remains stable for 90 days when stored in amber borosilicate glass at 4 °C. At the point of use, a 2.0 mL aliquot of the reagent is added to a 50 mL water sample pre-treated with hydroxylamine hydrochloride to reduce residual chlorine; the absorbance of the resulting violet complex is measured at 565 nm against a reagent blank within 15 minutes. The calibration curve, constructed with NIST SRM 3126a iron standard, shows linearity from 0.02 mg/L to 2.5 mg/L with a correlation coefficient r² ≥ 0.9995. The method detection limit, calculated per 40 CFR Part 136 Appendix B, is 8 µg/L. As the compound is classified as a laboratory chemical, shipment must comply with transport regulations for non-dangerous goods under IATA DGR when the inner packaging does not exceed 250 g per bottle, with a corresponding safety data sheet structured per GHS Revision 9 and transmitted in the ANSI Z400.1-format before international dispatch.
